The DOI matches its Crossref record.
Maraba Virus as a Potent Oncolytic Vaccine Vector
Open accessAbstract
The rhabdovirus Maraba has recently been characterized as a potent oncolytic virus. In the present study, we engineered an attenuated Maraba strain, defined as MG1, to express a melanoma-associated tumor antigen. Its ability to mount an antitumor immunity was evaluated in tumor-free and melanoma tumor-bearing mice. Alone, the MG1 vaccine appeared insufficient to prime detectable adaptive immunity against the tumor antigen. However, when used as a boosting vector in a heterologous prime-boost regimen, MG1 vaccine rapidly generated strong antigen-specific T-cell immune responses. Once applied for treating syngeneic murine melanoma tumors, our oncolytic prime-boost vaccination protocol involving Maraba MG1 dramatically extended median survival and allowed complete remission in more than 20% of the animals treated. This work describes Maraba virus MG1 as a potent vaccine vector for cancer immunotherapy displaying both oncolytic activity and a remarkable ability to boost adaptive antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0398-7 · Cited by 192
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Paillet, J., Plantureux, C., Lévesque, S., Le Naour, J., Stoll, G., Sauvat, A., Caudana, P., Tosello Boari, J., Bloy, N., Lachkar, S., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200853 · Cited by 41
Self-citationHDACi delivery reprograms tumor-infiltrating myeloid cells to eliminate antigen-loss variants
Nguyen, A., Ho, L., Workenhe, S. T., Chen, L., Samson, J., Walsh, S. R., Pol, J., Bramson, J. L., & Wan, Y. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.040 · Cited by 29
Metadata
- Authors
- Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S., Chen, L., Kazdhan, N., Bramson, J. L., Stojdl, D. F., Wan, Y., & Lichty, B. D.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 22
- Issue
- 2
- Pages
- 420-429
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2036869628
- Cited by
- 173
- References
- 0
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maraba Virus as a Potent Oncolytic Vaccine Vector. https://app.cochat.ai/papers/10.1038/mt.2013.249
- The paper
- Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S., Chen, L., Kazdhan, N., Bramson, J. L., Stojdl, D. F., Wan, Y., & Lichty, B. D. (2014). Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy. https://doi.org/10.1038/mt.2013.249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.